The effect of compound Ma-ol-asal of chronic obstructive pulmonary disease (COPD) patients

Phase 2

• Conditions: Chronic Obstructive Pulmonary Disease (COPD).; Chronic obstructive pulmonary disease, unspecified; J44.9

• Registration Number: IRCT20190217042737N2
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Patients with COPD referring to the lung clinic
People who are willing to participate in the study.

Exclusion Criteria

Very severe COPD require hospitalization
Underlying illnesses, such as CF, Broncho-pulmonary dysplasia, heart failure, broncho-tracheomalacia, bronchiectasis, pulmonary embolism and sarcoidosis.
Taking drugs such as aspirin, beta-blocker and NSAID.
Allergic to any of the components of Ma-ol-asal

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical symptoms. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after commencing consumption of the compound syrup. Method of measurement: CAT questionnaire.;Quality of life. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after commencing consumption of the compound syrup. Method of measurement: The St George's respiratory questionnaire.

Secondary Outcome Measures

Name	Time	Method
Respiratory test changes in FEV1, FEV1 / FVC. Timepoint: At the beginning of the study (before the intervention) and 8 weeks after commencement of the administration of the compound syrup. Method of measurement: Pulmonary functional test.